Kailera has enrolled about 4,900 participants in its Phase 3 KaiNETIC programme, including a direct comparison of ribupatide with semaglutide, with results now expected in mid-2028.
Kailera Therapeutics has finished enrolling participants in its KaiNETIC late-stage programme, pushing results on its obesity injection ribupatide into 2028 and keeping the market waiting for one of the more closely watched tests in the weight-loss drug race. The company said on 30 September that recruitment had ended across all three Phase 3 trials, which together have drawn roughly 4,900 adults to study sites in more than 200 locations across 11 countries.
The trials are designed to run for 76 weeks each and examine weekly doses of up to 10 mg, with participants gradually moved on to treatment over as long as 24 weeks before entering a maintenance period. KaiNETIC-1 is focused on adults with obesity, or overweight with a related health condition, but without type 2 diabetes. KaiNETIC-2 is studying patients with obesity and type 2 diabetes, and will measure both body weight and haemoglobin A1c, a standard marker of longer-term blood sugar control.
The most notable study is KaiNETIC-3, which is testing ribupatide against both placebo and open-label semaglutide 2.4 mg, the active ingredient in Novo Nordisk’s Wegovy. That direct comparison is unusual in obesity drug development and suggests Kailera is not merely aiming to show a benefit over placebo, but to argue that its drug can compete with an established market leader. The trial is enrolling adults with a body mass index of 35 or higher and no type 2 diabetes, a group the company says may need greater weight loss.
Kailera said topline data from the full programme are now expected in mid-2028. In a statement, chief medical officer Scott Wasserman said obesity remains a chronic and complex disease and that completing recruitment brings the company closer to what it hopes could be a best-in-class treatment. The company has not reported efficacy or safety results from the Phase 3 programme, so the announcement is about timing and scope rather than performance.
There is, however, some earlier evidence behind the programme. According to Kailera, ribupatide has already been studied in more than 3,000 people for periods of up to 52 weeks, including late-stage work run by Hengrui in China. Kailera holds exclusive rights outside Greater China, after a licensing deal announced in 2024. The company is also developing an oral version of ribupatide for China and says it plans global Phase 3 trials of that pill in the first half of 2027, alongside other pipeline assets including a once-daily GLP-1 tablet and a separate injectable that also targets glucagon receptors.
The wider interest in these trials goes beyond obesity treatment alone. Weight-loss medicines have become central to discussions about metabolic health and longevity because excess weight is linked to a range of age-related diseases. Yet the crucial question remains whether larger and more durable weight loss can translate into longer, healthier lives. For now, Kailera’s study design is what matters most: it is a substantial attempt to determine whether ribupatide can match or surpass semaglutide, but the answer will not be known until 2028.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
